<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184493</url>
  </required_header>
  <id_info>
    <org_study_id>Celebrex for HCC</org_study_id>
    <nct_id>NCT03184493</nct_id>
  </id_info>
  <brief_title>Celebrex and Metformin for Postoperative Hepatocellular Carcinoma</brief_title>
  <acronym>XBD</acronym>
  <official_title>Celebrex and Metformin for Postoperative Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangxi Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Guangxi Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective trial aims to compare the role of celebrex alone, metformin alone, and
      celebrex plus metformin in preventing HCC recurrence after hepatic resection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hepatic resection is a popular curative treatment for patients with early-stage HCC and
      well-preserved liver function. Although overall survival after resection has been increasing,
      the median 5-year disease-free survival rate after resection remains at only about 37% for
      early-stage HCC. In fact, the 5-year recurrence rate is as high as 74% for intermediate and
      advanced HCC. Postoperative recurrence may be due to intrahepatic metastasis arising from the
      primary tumor or it may be de novo metastasis (multicentric) that arises spontaneously in the
      residual liver. Intrahepatic metastasis is the primary mechanism of early recurrence, which
      occurs &lt;2 years after resection; multicentric metastasis is the principal mechanism behind
      late recurrence, which occurs at least 2 years after resection.

      In the past few years, some observational studies with small sample size found metformin and
      celebrex (selective cyclic oxidase-2 inhibitors) may reduce the rate of HCC after surgery.
      However, no prospective study compare their efficacy in preventing HCC recurrence. This trial
      aims to compare the role of celebrex alone, metformin alone, and celebrex plus metformin in
      preventing HCC recurrence after hepatic resection.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with tumor recurrence</measure>
    <time_frame>1-year</time_frame>
    <description>The 1-year tumor recurrence will be compared between the three groups</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Celebrex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celebrex plus Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive celebrex (1 piece/day, 0.2mg/piece, Pfizer Pharmaceuticals Ltd) until obvious side effects. In addition, patients will receive metformin (1 piece/bid, 250 mg/piece) until obvious side effects.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Empty control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>This group patients will not receive any postoperative adjuvant therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex plus Metformin</intervention_name>
    <description>This group patients will receive metformin and celebrex.</description>
    <arm_group_label>Celebrex plus Metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celebrex</intervention_name>
    <description>This group patients will receive celebrex.</description>
    <arm_group_label>Celebrex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>This group patients will receive metformin.</description>
    <arm_group_label>Metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-75 years

          -  Diagnosis of HCC was confirmed by histopathological examination of surgical samples in
             all patients

          -  Patients have Child-Pugh A or B liver function

          -  No previous neoadjuvant treatment

          -  No evidence of macrovascular invasion, metastasis to the lymph nodes and/or distant
             metastases on the basis of preoperative imaging results and perioperative findings

          -  No malignancy other than HCC for 5 years prior to the initial HCC treatment

        Exclusion Criteria:

          -  History of cardiac disease

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known Central Nervous System tumors including metastatic brain disease

          -  History of organ allograft

          -  Substance abuse, medical, psychological or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Any condition that is unstable or which could jeopardize the safety of the patient and
             his/her compliance in the study Pregnant or breast-feeding patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Bang-De Xiang, PhD</last_name>
    <phone>0771-5330855</phone>
    <email>xiangbangde@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Affiliated Tumor Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanjing</city>
        <state>Guangxi</state>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bang-de Xiang, PhD</last_name>
      <phone>7715330855</phone>
      <email>xiangbangde@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Zhong JH, Ma L, Li LQ. Postoperative therapy options for hepatocellular carcinoma. Scand J Gastroenterol. 2014 Jun;49(6):649-61. doi: 10.3109/00365521.2014.905626. Epub 2014 Apr 10. Review.</citation>
    <PMID>24716523</PMID>
  </reference>
  <reference>
    <citation>Ling S, Song L, Fan N, Feng T, Liu L, Yang X, Wang M, Li Y, Tian Y, Zhao F, Liu Y, Huang Q, Hou Z, Xu F, Shi L, Li Y. Combination of metformin and sorafenib suppresses proliferation and induces autophagy of hepatocellular carcinoma via targeting the mTOR pathway. Int J Oncol. 2017 Jan;50(1):297-309. doi: 10.3892/ijo.2016.3799. Epub 2016 Dec 9.</citation>
    <PMID>27959383</PMID>
  </reference>
  <reference>
    <citation>Kim G, Jang SY, Han E, Lee YH, Park SY, Nam CM, Kang ES. Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int J Cancer. 2017 Feb 15;140(4):798-806. doi: 10.1002/ijc.30506. Epub 2016 Nov 16.</citation>
    <PMID>27861855</PMID>
  </reference>
  <reference>
    <citation>Chan KM, Kuo CF, Hsu JT, Chiou MJ, Wang YC, Wu TH, Lee CF, Wu TJ, Chou HS, Lee WC. Metformin confers risk reduction for developing hepatocellular carcinoma recurrence after liver resection. Liver Int. 2017 Mar;37(3):434-441. doi: 10.1111/liv.13280. Epub 2016 Nov 13.</citation>
    <PMID>27775209</PMID>
  </reference>
  <reference>
    <citation>Zhou YY, Zhu GQ, Liu T, Zheng JN, Cheng Z, Zou TT, Braddock M, Fu SW, Zheng MH. Systematic Review with Network Meta-Analysis: Antidiabetic Medication and Risk of Hepatocellular Carcinoma. Sci Rep. 2016 Sep 19;6:33743. doi: 10.1038/srep33743.</citation>
    <PMID>27642100</PMID>
  </reference>
  <reference>
    <citation>Tong H, Wei B, Chen S, Xie YM, Zhang MG, Zhang LH, Huang ZY, Tang CW. Adjuvant celecoxib and lanreotide following transarterial chemoembolisation for unresectable hepatocellular carcinoma: a randomized pilot study. Oncotarget. 2017 Jul 18;8(29):48303-48312. doi: 10.18632/oncotarget.15684.</citation>
    <PMID>28430638</PMID>
  </reference>
  <reference>
    <citation>Tong H, Li X, Wei B, Tang C. Combinative treatment of transarterial chemoembolization, celecoxib and lanreotide in unresectable hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 2015 Oct;39(5):e65-6. doi: 10.1016/j.clinre.2015.01.008. Epub 2015 Mar 4.</citation>
    <PMID>25746137</PMID>
  </reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2017</study_first_posted>
  <last_update_submitted>June 9, 2017</last_update_submitted>
  <last_update_submitted_qc>June 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangxi Medical University</investigator_affiliation>
    <investigator_full_name>Jian-Hong Zhong</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

